ankylosing spondylitis
Rheumatology · 2006–2025
39decisions
12medicines
15carried consumer input
8individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| etanercept General Schedule Authority Required and Section 100 (Highly Specialised Drugs Program) Authority Required listings for severe psoriatic arthritis, ankylosing… | Jul 2025 | Recommended with restriction | none received |
| infliximab Rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to reference infliximab for multiple indications: rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children/adolescents 6–17… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| infliximab Continuing treatment and balance of supply of infliximab 120 mg subcutaneous injection for ankylosing spondylitis, severe Crohn disease, severe chronic plaque… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| bimekizumab Treatment of radiographically confirmed (active) ankylosing spondylitis (AS) in adults who have failed to achieve an adequate response following treatment with… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia |
| tofacitinib Treatment of adult patients with active ankylosing spondylitis who have failed to achieve an adequate response following treatment with at least 2 NSAIDs or… | Mar 2023 | Recommended with restriction | 1 individuals Musculoskeletal Australia |
| infliximab Treatment of ankylosing spondylitis (AS), severe chronic plaque psoriasis (CPP), severe active psoriatic arthritis (PsA), and complex refractory fistulising… | Mar 2022 | Recommended | unclear |
| adalimumab; upadacitinib Change in restriction levels (Authority Required categories) for adalimumab across multiple indications (rheumatoid arthritis, ankylosing spondylitis,… | Nov 2022 | Noted | 1 individuals |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2021 | Recommended | unclear |
| secukinumab Amendment request to increase maximum quantity from one to two injections and reduce repeats from five to two for continuing treatment of ankylosing… | Jul 2021 | Not recommended | none received |
| upadacitinib Treatment of adults with ankylosing spondylitis (AS) following inadequate response to at least two non-steroidal anti-inflammatory drugs (NSAIDs) combined with… | Mar 2021 | Recommended with restriction | none received |
| etanercept Biosimilar to Enbrel for severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile… | Nov 2021 | Recommended with restriction | unclear |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| ixekizumab Treatment of adult patients with active ankylosing spondylitis (AS). Radiographically confirmed active ankylosing spondylitis in adults. | Jul 2020 | Recommended with restriction | input received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| etanercept Administrative request to change listing restrictions and authority level for etanercept biosimilar (Brenzys) to support biosimilar uptake in rheumatoid… | Dec 2020 | Not recommended | no section in document |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Treatment of severe active rheumatoid arthritis, moderate to severe ulcerative colitis, and severe refractory Crohn's disease in adult patients via… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Increase in maximum quantity from 4 to 5 vials for subsequent continuing treatment of severe Crohn disease, complex refractory fistulising Crohn disease,… | Mar 2019 | Recommended with restriction | 3 individuals |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile severe chronic plaque… | Mar 2018 | Recommended with restriction | none received |
| etanercept Changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including modifications to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| etanercept Severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis. | Aug 2017 | Recommended with restriction | no section in document |
| certolizumab pegol Treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, and active ankylosing spondylitis. | Mar 2017 | Recommended with restriction | none received |
| infliximab Change to initial and continuing treatment restrictions for infliximab biosimilar, and application of biosimilar uptake measures for multiple indications… | Nov 2017 | Recommended with restriction | none received |
| etanercept Biosimilar etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended with restriction | input received |
| certolizumab pegol Loading dose administration in patients with ankylosing spondylitis, severe psoriatic arthritis, and severe active rheumatoid arthritis to reduce patient… | Mar 2016 | Recommended | no section in document |
| secukinumab Treatment of ankylosing spondylitis in adults. | Mar 2016 | Recommended with restriction | none received |
| infliximab Biosimilar infliximab for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis,… | Nov 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade, indicated for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| certolizumab pegol Treatment of adults with active ankylosing spondylitis (AS) who have been intolerant to or have had inadequate response to at least one nonsteroidal… | Mar 2014 | Recommended with restriction | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients requiring an NSAID who are at increased risk of… | Jul 2013 | Not recommended | no section in document |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Mar 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of developing… | Nov 2012 | Not recommended | unclear |
| naproxen and esomeprazole Symptomatic treatment of osteoarthritis, rheumatoid arthritis or ankylosing spondylitis in patients who require an NSAID and are at high risk of… | Nov 2012 | Not recommended | unclear |
| golimumab Treatment of adult patients with active ankylosing spondylitis. | Mar 2010 | Recommended with restriction | no section in document |
| adalimumab Treatment of adults with ankylosing spondylitis who have had an inadequate response to conventional therapy. | Nov 2006 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · Australasian Society of Clinical Immunology and Allergy · CreakyJoints Australia · Musculoskeletal Australia
What the PBS pays
$1,324M in government benefit over 2024–25, across 13,510,472 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| upadacitinib | $291.6M |
| adalimumab | $241.9M |
| secukinumab | $120.2M |
| golimumab | $97.7M |
| Naproxen and esomeprazole | $84.5M |
| naproxen and esomeprazole | $84.5M |
| infliximab | $83.8M |
| etanercept | $79.8M |
| ixekizumab | $70M |
| tofacitinib | $57.8M |
| certolizumab pegol | $57.5M |
| bimekizumab | $54.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 6 technologies for this condition, recommending 6 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| tofacitinibTofacitinib for treating active ankylosing spondylitis | TA920 | recommended restricted | 2023-10 |
| bimekizumabBimekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA918 | recommended restricted | 2023-10 |
| upadacitinibUpadacitinib for treating active ankylosing spondylitis | TA829 | recommended restricted | 2022-09 |
| ixekizumabIxekizumab for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA718 | recommended restricted | 2021-07 |
| secukinumabSecukinumab for treating active ankylosing spondylitis | TA407 | recommended restricted | 2016-09 |
| tnf alpha inhibitorsTNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis | TA383 | recommended | 2016-02 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| celecoxibANACOXIB Celecoxib 100 mg capsule blister pack | 1999 | 49 |
| piroxicamAPO-PIROXICAM piroxicam 10mg capsule blister pack | 1992 | 9 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 15 of 33 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.